EUVIMEDEUVIMED entdecken
Crossref

New Benzimidazole Scaffolds Tagged With Isatin/Thiourea Motifs as Anti‐Cancer Agents: Promising Approach for VEGFR‐2 Inhibition

Alaa M Ali iD, Bhoomendra A Bhongade iD, Samar S Tawfik, Mohammed A M Massoud, Amany S Mostafa iD

Archiv der Pharmazie · 2026-02 · 359 (2)

DOI: 10.1002/ardp.70217 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, online erschienen am 28.02.2026. Verfasst von Alaa M Ali und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor Receptor-2, Benzimidazoles, Antineoplastic Agents, Thiourea. Die Arbeit nennt 58 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inspired by the structural insights of the reported kinase inhibitor Sorafenib, two new series comprising 19 benzimidazole‐based compounds incorporating isatin and thiourea motifs were rationally designed as a novel VEGFR‐2‐targeting anti‐cancer chemotype. These compounds were synthesized and evaluated for their anti‐cancer activity using the NCI single‐dose antiproliferative assay against 60 cancer cell lines. The most potent and broad‐spectrum compounds 8e , 9b , 9d , 9e , 9g , 9h , and 9i were further selected by NCI for the five‐dose assay panel. These compounds were then assessed for anti‐angiogenic activity against VEGFR‐2, where compound 9i revealed promising activity (IC 50 = 58 nM) compared to Sorafenib (IC 50 = 72 nM), while the rest of the compounds gave an IC 50 range of 96–981 nM. The most active compound 9i showed considerable safety toward normal human WI‐38 cells (IC 50 = 28.847 µM vs. Sorafenib IC 50 = 13.497 µM) and arrested cell growth in the G1/S phase with total apoptotic induction of 37.65%. Molecular docking studies revealed favorable binding modes of the designed compounds within the VEGFR‐2 active site. Molecular dynamics (MD) simulation confirmed the high stability of VEGFR‐2— 9i complex. Physicochemical properties and bioavailability radar plot disclosed adequate drug‐likeness properties. Collectively, a new benzimidazole‐isatin/thiourea chemotype was introduced as a promising VEGFR‐2‐targeting anti‐cancer scaffold, demonstrating enhanced potency and improved safety relative to Sorafenib, and providing a rational basis for further lead optimization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vascular Endothelial Growth Factor Receptor-2BenzimidazolesAntineoplastic AgentsThioureaProtein Kinase InhibitorsHumansStructure-Activity RelationshipCell ProliferationMolecular StructureMolecular Docking SimulationDrug Screening Assays, AntitumorDose-Response Relationship, DrugCell Line, TumorApoptosisAngiogenesis InhibitorsDrug Design

Stichwörter der Autor:innen

MD simulationVEGFR‐2anticanceranti‐angiogenicbenzimidazole

Substanzen

Vascular Endothelial Growth Factor Receptor-2BenzimidazolesAntineoplastic AgentsThioureaKDR protein, humanProtein Kinase InhibitorsAngiogenesis Inhibitors

Autor:innen und Institutionen

  • Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
  • Department of Pharmaceutical Chemistry, RAK College of Pharmacy, RAK Medical & Health Sciences University, Ras Al Khaimah, United Arab Emirates.
  • Pharmacy Center of Scientific Excellence, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.

ORCID-Profile: Alaa M Ali, Bhoomendra A Bhongade, Amany S Mostafa

Zitieren

APA

Ali, A. M., Bhongade, B. A., Tawfik, S. S., Massoud, M. A. M., & Mostafa, A. S. (2026). New Benzimidazole Scaffolds Tagged With Isatin/Thiourea Motifs as Anti‐Cancer Agents: Promising Approach for VEGFR‐2 Inhibition. Archiv der Pharmazie, 359(2). https://doi.org/10.1002/ardp.70217

Vancouver

Ali AM, Bhongade BA, Tawfik SS, Massoud MAM, Mostafa AS. New Benzimidazole Scaffolds Tagged With Isatin/Thiourea Motifs as Anti‐Cancer Agents: Promising Approach for VEGFR‐2 Inhibition. Archiv der Pharmazie. 2026;359(2). doi:10.1002/ardp.70217

BibTeX
@article{Ali2026,
  author = {Ali, Alaa M and Bhongade, Bhoomendra A and Tawfik, Samar S and Massoud, Mohammed A M and Mostafa, Amany S},
  title = {New Benzimidazole Scaffolds Tagged With Isatin/Thiourea Motifs as Anti‐Cancer Agents: Promising Approach for VEGFR‐2 Inhibition},
  journal = {Archiv der Pharmazie},
  year = {2026},
  volume = {359},
  number = {2},
  doi = {10.1002/ardp.70217}
}
Kostenlos starten →